]>
IRCT20090804002288N19 IRCT 2026-05-06 Bagheiat-allah University of Medical Sciences Effects of feverfew (Tanacetum Parthenium) on the knee osteoarthritis symptoms Study on the effects of Tanacetum Parthenium (feverfew) on the symptoms of knee osteoarthritis: A randomized controlled clinical trial 2026-06-22 anticipated 64 Complete https://irct.ir/trial/89566 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomization method using random blocks and random numbers table are employed.The patients are randomly divided into two groups A and B. One group receives the drug and the other group receives placebo. Sealed envelopes are used for concealment of allocation of the patients to the groups A and B. The patients numbers are written on the outsides of the envelopes and allocations to the groups A or B are written on the insides of the envelopes. Each patient selects one envelope, Blinding description: Bottles of drug and placebo are labeled with the code B or A. Other specifications on the labels are identical. Physician, nurse, patients, data collectors and those who evaluate the outcomes are unaware of the drug and placebo groups. Patients are aware that they are either in the drug or placebo group, but they are not aware of the type of group they are in. 3 Primary knee osteoarthritis. Intervention 1: Intervention group: Patients of this group consume one capsule containing 250 mg standardized hydro-alcoholic extract of Tanacetum Parthenium every 12 hours after meal for 2 months. Intervention 2: Control group: Patients of this group consume one placebo capsule containing 250 mg toasted powder every 12 hours after meal for 2 months. Yes - There is a plan to make this available What will be shared: All data after de-identification can be shared. When: Data are available one year after publication of the results for an infinite period of time. To whom: Data and documents will be available only for people working in academic institutions. Conditions: No analysis on data or documents is permitted. Use of data and documents is permitted only with citation of the article in which they were published. The applicant for data or documents should mention the aim for access to data or documents. Where to obtain: Application for data or documents should be sent to Dr. Akram Rostamzadeh with the email rostamzadehak@yahoo.com How to obtain: The applicant for data or documents should mention the reason and aim for the application. The application will be answered within at most 2 weeks. Comments:
public Akram Rostamzadeh
Mollasadra
Tehran Iran (Islamic Republic of) 1435915371 +98 21 8805 0435 rostamzadehak@yahoo.com Bagheiat-allah University of Medical Sciences scientific Akram Rostamzadeh
Mollasadra
Tehran Iran (Islamic Republic of) 143595371 +98 21 8805 0435 rostamzadehak@yahoo.com Bagheiat-allah University of Medical Sciences Iran (Islamic Republic of) Diagnosis of knee osteoarthritis (grade 2 to 3 based on radiological criteria) Age between 40 and 80 years Ability of taking oral drugs and cooperation with treatment follow-up 40 years 80 years Both Secondary osteoarthritis History of knee surgery or knee injection within the past 6 months Severe systemic diseases (cardiac, hepatic, renal, infectious) Coagulopathies or use of anticoagulant drugs Pregnancy, breastfeeding, or planning for pregnancy History of allergy to plants of the Asteraceae family (e.g., chicory, artichoke, daisy, sunflower) M17.1 Primary gonarthrosis Treatment - Drugs Placebo Intervention group: Patients of this group consume one capsule containing 250 mg standardized hydro-alcoholic extract of Tanacetum Parthenium every 12 hours after meal for 2 months. Control group: Patients of this group consume one placebo capsule containing 250 mg toasted powder every 12 hours after meal for 2 months. Total extent of knee osteoarthritis symptoms. Timepoint: At the start of study, and 1 and 2 months after intervention. Method of measurement: Western Ontario and McMaster Universities Osteoarthritis Arthritis Index questionnaire. Degree of patients satisfaction. Timepoint: At the start of study and 2 months after intervention. Method of measurement: Ten centimeter ruler. Serum glutamic oxaloacetic transaminase. Timepoint: At the start and 2 months after intervention. Method of measurement: Autoanalyzer. Serum glutamic pyruvic transaminase. Timepoint: At the start and 2 months after intervention. Method of measurement: Autoanalyzer. Blood creatinine. Timepoint: At the start and 2 months after intervention. Method of measurement: Autoanalyzer. Blood Urea Nitrogen. Timepoint: At the start and 2 months after intervention. Method of measurement: Autoanalyzer. Complete Blood Count. Timepoint: At the start and 2 months after intervention. Method of measurement: Autoanalyzer. Prothrombin Time. Timepoint: At the start and 2 months after intervention. Method of measurement: Autoanalyzer. Partial Thromboplastin Time. Timepoint: At the start and 2 months after intervention. Method of measurement: Autoanalyzer. Drug side effects. Timepoint: During the study. Method of measurement: Patient report and blood tests. Extent of knee joint pain. Timepoint: At the start and 1 and 2 months after intervention. Method of measurement: Western Ontario and McMaster Universities Arthritis Index questionnaire. Extent of knee joint stiffness. Timepoint: At the start and 1 and 2 months after intervention. Method of measurement: Western Ontario and McMaster Universities Arthritis Index questionnaire. Extent of patient physical function. Timepoint: At the start and 1 and 2 months after intervention. Method of measurement: Western Ontario and McMaster Universities Arthritis Index questionnaire. Bagheiat-allah University of Medical Sciences Approved 2026-02-02 Ethics Committee of Bagheiat-Allah University of medical sciences Bagheiat-Allah University of medical sciences, Sheikh bahaee Street, Tehran. Iran Tehran Tehran Iran (Islamic Republic of)